Tempus AI Named to TIME's 10 Most Influential Health Companies of 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy TEM?
Source: Newsfilter
- Industry Recognition: Tempus AI has been named one of TIME's 10 Most Influential Health and Life Science Companies of 2026, highlighting its innovation and impact in precision medicine, particularly in genomic testing and clinical analysis.
- FDA-Approved Testing Innovation: The xT CDx test, recognized by TIME, is a 648-gene tissue-based NGS test for molecular profiling of all malignant solid tumors, enhancing personalized treatment outcomes for patients and solidifying the company's market position.
- Strategic Acquisition Integration: Tempus' acquisition of Ambry Genetics has strengthened its capabilities in germline and pediatric areas, integrating comprehensive genomic data and enhancing its competitive edge within the precision medicine ecosystem.
- Partnership Expansion: Collaborations with AstraZeneca and Pathos AI aim to develop the largest multimodal foundation model in oncology, showcasing Tempus' strategic vision in advancing healthcare data intelligence and driving technological progress in the industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEM
Wall Street analysts forecast TEM stock price to rise
9 Analyst Rating
4 Buy
5 Hold
0 Sell
Moderate Buy
Current: 55.000
Low
76.00
Averages
84.38
High
105.00
Current: 55.000
Low
76.00
Averages
84.38
High
105.00
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of ARKK ETF's 52-Week Price Fluctuations
- Price Range Analysis: The ARKK ETF has a 52-week low of $48.53 and a high of $92.65, with the latest trade at $76.22, indicating significant volatility over the past year and reflecting varying market perceptions of its portfolio.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide investors with valuable insights for technical analysis, helping to assess whether the current price is overvalued or undervalued, thus influencing investment decisions.
- ETF Unit Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are buying and selling “units” that can be created or destroyed based on investor demand, providing flexibility that enhances ETF adaptability during market fluctuations.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), as such liquidity changes can impact the individual components held within the ETFs.
See More
Tempus AI Named to TIME's 10 Most Influential Health Companies of 2026
- Industry Recognition: Tempus AI has been named one of TIME's 10 Most Influential Health and Life Science Companies of 2026, highlighting its innovation and impact in precision medicine, particularly in genomic testing and clinical analysis.
- FDA-Approved Testing Innovation: The xT CDx test, recognized by TIME, is a 648-gene tissue-based NGS test for molecular profiling of all malignant solid tumors, enhancing personalized treatment outcomes for patients and solidifying the company's market position.
- Strategic Acquisition Integration: Tempus' acquisition of Ambry Genetics has strengthened its capabilities in germline and pediatric areas, integrating comprehensive genomic data and enhancing its competitive edge within the precision medicine ecosystem.
- Partnership Expansion: Collaborations with AstraZeneca and Pathos AI aim to develop the largest multimodal foundation model in oncology, showcasing Tempus' strategic vision in advancing healthcare data intelligence and driving technological progress in the industry.
See More
Median Technologies Secures FDA 510(k) Clearance for eyonis® LCS, Accelerating U.S. Commercialization
- U.S. Market Access: Median Technologies has successfully secured FDA 510(k) clearance for eyonis® LCS, accelerating its commercialization efforts and expected to provide lung cancer screening services to approximately 14.5 million eligible individuals in the U.S., significantly enhancing the company's market share in cancer diagnostics.
- Reduction in Operating Loss: In 2025, Median Technologies achieved a 28% year-over-year reduction in operating loss, decreasing from €16.3 million in 2024 to €11.6 million in 2025, reflecting substantial improvements in cost control and operational efficiency, thereby boosting investor confidence.
- Record Order Backlog: As of March 31, 2026, Median's iCRO order backlog reached a record €79.8 million, representing a 4.2% increase from €76.6 million in December 2025, providing strong revenue visibility for the coming years.
- Stable Cash Flow: As of March 31, 2026, the company reported cash and cash equivalents of €14.0 million, with the potential to raise up to €44.4 million through the exercise of 2025 warrants, ensuring stable cash flow through year-end 2026 to support the execution of its strategic priorities.
See More
Tempus and Predicta Launch Co-Branded Genomic Sequencing Assay
- Joint Launch of New Assay: Tempus AI and Predicta Biosciences announced the commercial expansion of the GenoPredicta™ genomic sequencing assay, aimed at comprehensive characterization of hematologic malignancies and measurable residual disease (MRD) monitoring, significantly enhancing diagnostic accuracy in clinical settings.
- Ultra-High Sensitivity: The GenoPredicta assay extracts deep genetic insights from as few as 50 tumor cells, achieving a sensitivity as low as one in a million, which expands testing eligibility to cases with low tumor burden, thereby increasing treatment opportunities for patients.
- Integrated Technology Advantage: By combining flow cytometry with whole-genome sequencing, the assay delivers 100% concordance between peripheral blood and bone marrow, sparing patients from invasive biopsies while providing researchers with deeper insights into disease biology.
- Accelerated Market Adoption: Predicta's CEO stated that this partnership with Tempus will accelerate market adoption and optimize the utility of clinical trials, further advancing the development of precision medicine and enabling smarter treatment decisions for physicians.
See More
Tempus AI Announces 31 Abstracts for AACR Annual Meeting 2026
- Research Highlights: Tempus AI will present 31 abstracts, including one oral presentation, at the 2026 AACR Annual Meeting, emphasizing the real-world impact of its multimodal datasets and AI diagnostic solutions, which are expected to transform cancer diagnosis and treatment.
- Gene Fusion Insights: In a study of 30,884,099 colorectal cancer patients, the co-occurrence of microsatellite instability (MSI) and gene fusions was significantly enriched in MSI tumors at 6.2% compared to 2.2% in MSS tumors, providing new stratification criteria for clinical treatment.
- Clinical Significance of KMT2C Mutations: The analysis revealed that patients with KMT2C mutations had a real-world overall survival (rwOS) of 19.6 months post-platinum chemotherapy, compared to 16.7 months for non-mutated patients, with colorectal cancer patients showing a median rwOS of 51.0 months, highlighting its potential as a predictive biomarker.
- Machine Learning in SCLC: The research team developed a machine learning model analyzing genomic and transcriptomic data from approximately 1,400 small cell lung cancer patients, finding that nearly 30% of those with RB1 genomic alterations still exhibited RB function, challenging traditional beliefs and potentially influencing future treatment strategies.
See More
Latest Wall Street Ratings Overview
- Tesla Rating Maintained: Wells Fargo reiterates its underweight rating on Tesla ahead of earnings, indicating a cautious outlook due to limited progress on Robotaxi and Optimus, suggesting a strategic pivot towards Semi and Roadster could be necessary for future growth.
- Starbucks Rating Upgrade: Jefferies upgrades Starbucks from sell to hold, citing stabilization in the U.S. market, and while the stock trades at a high premium, the expectation of more realistic earnings estimates reflects a more optimistic view on the company's future performance.
- Nokia Transformation: Bank of America upgrades Nokia from neutral to buy, highlighting its transition into an optical powerhouse, which positions the company favorably in the telecom equipment market and suggests significant growth potential ahead.
- Chime Financial Rating Initiated: Wells Fargo initiates coverage on Chime Financial with an overweight rating, recognizing its strong growth and profitability in the digital banking sector, and anticipates a positive impact from the upcoming tax season.
See More
Analysis of ARKK ETF's 52-Week Price Fluctuations
- Price Range Analysis: The ARKK ETF has a 52-week low of $48.53 and a high of $92.65, with the latest trade at $76.22, indicating significant volatility over the past year and reflecting varying market perceptions of its portfolio.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide investors with valuable insights for technical analysis, helping to assess whether the current price is overvalued or undervalued, thus influencing investment decisions.
- ETF Unit Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are buying and selling “units” that can be created or destroyed based on investor demand, providing flexibility that enhances ETF adaptability during market fluctuations.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs focuses on those experiencing notable inflows (new units created) or outflows (old units destroyed), as such liquidity changes can impact the individual components held within the ETFs.
See More
Tempus AI Named to TIME's 10 Most Influential Health Companies of 2026
- Industry Recognition: Tempus AI has been named one of TIME's 10 Most Influential Health and Life Science Companies of 2026, highlighting its innovation and impact in precision medicine, particularly in genomic testing and clinical analysis.
- FDA-Approved Testing Innovation: The xT CDx test, recognized by TIME, is a 648-gene tissue-based NGS test for molecular profiling of all malignant solid tumors, enhancing personalized treatment outcomes for patients and solidifying the company's market position.
- Strategic Acquisition Integration: Tempus' acquisition of Ambry Genetics has strengthened its capabilities in germline and pediatric areas, integrating comprehensive genomic data and enhancing its competitive edge within the precision medicine ecosystem.
- Partnership Expansion: Collaborations with AstraZeneca and Pathos AI aim to develop the largest multimodal foundation model in oncology, showcasing Tempus' strategic vision in advancing healthcare data intelligence and driving technological progress in the industry.
See More
Median Technologies Secures FDA 510(k) Clearance for eyonis® LCS, Accelerating U.S. Commercialization
- U.S. Market Access: Median Technologies has successfully secured FDA 510(k) clearance for eyonis® LCS, accelerating its commercialization efforts and expected to provide lung cancer screening services to approximately 14.5 million eligible individuals in the U.S., significantly enhancing the company's market share in cancer diagnostics.
- Reduction in Operating Loss: In 2025, Median Technologies achieved a 28% year-over-year reduction in operating loss, decreasing from €16.3 million in 2024 to €11.6 million in 2025, reflecting substantial improvements in cost control and operational efficiency, thereby boosting investor confidence.
- Record Order Backlog: As of March 31, 2026, Median's iCRO order backlog reached a record €79.8 million, representing a 4.2% increase from €76.6 million in December 2025, providing strong revenue visibility for the coming years.
- Stable Cash Flow: As of March 31, 2026, the company reported cash and cash equivalents of €14.0 million, with the potential to raise up to €44.4 million through the exercise of 2025 warrants, ensuring stable cash flow through year-end 2026 to support the execution of its strategic priorities.
See More
Tempus and Predicta Launch Co-Branded Genomic Sequencing Assay
- Joint Launch of New Assay: Tempus AI and Predicta Biosciences announced the commercial expansion of the GenoPredicta™ genomic sequencing assay, aimed at comprehensive characterization of hematologic malignancies and measurable residual disease (MRD) monitoring, significantly enhancing diagnostic accuracy in clinical settings.
- Ultra-High Sensitivity: The GenoPredicta assay extracts deep genetic insights from as few as 50 tumor cells, achieving a sensitivity as low as one in a million, which expands testing eligibility to cases with low tumor burden, thereby increasing treatment opportunities for patients.
- Integrated Technology Advantage: By combining flow cytometry with whole-genome sequencing, the assay delivers 100% concordance between peripheral blood and bone marrow, sparing patients from invasive biopsies while providing researchers with deeper insights into disease biology.
- Accelerated Market Adoption: Predicta's CEO stated that this partnership with Tempus will accelerate market adoption and optimize the utility of clinical trials, further advancing the development of precision medicine and enabling smarter treatment decisions for physicians.
See More
Tempus AI Announces 31 Abstracts for AACR Annual Meeting 2026
- Research Highlights: Tempus AI will present 31 abstracts, including one oral presentation, at the 2026 AACR Annual Meeting, emphasizing the real-world impact of its multimodal datasets and AI diagnostic solutions, which are expected to transform cancer diagnosis and treatment.
- Gene Fusion Insights: In a study of 30,884,099 colorectal cancer patients, the co-occurrence of microsatellite instability (MSI) and gene fusions was significantly enriched in MSI tumors at 6.2% compared to 2.2% in MSS tumors, providing new stratification criteria for clinical treatment.
- Clinical Significance of KMT2C Mutations: The analysis revealed that patients with KMT2C mutations had a real-world overall survival (rwOS) of 19.6 months post-platinum chemotherapy, compared to 16.7 months for non-mutated patients, with colorectal cancer patients showing a median rwOS of 51.0 months, highlighting its potential as a predictive biomarker.
- Machine Learning in SCLC: The research team developed a machine learning model analyzing genomic and transcriptomic data from approximately 1,400 small cell lung cancer patients, finding that nearly 30% of those with RB1 genomic alterations still exhibited RB function, challenging traditional beliefs and potentially influencing future treatment strategies.
See More
Latest Wall Street Ratings Overview
- Tesla Rating Maintained: Wells Fargo reiterates its underweight rating on Tesla ahead of earnings, indicating a cautious outlook due to limited progress on Robotaxi and Optimus, suggesting a strategic pivot towards Semi and Roadster could be necessary for future growth.
- Starbucks Rating Upgrade: Jefferies upgrades Starbucks from sell to hold, citing stabilization in the U.S. market, and while the stock trades at a high premium, the expectation of more realistic earnings estimates reflects a more optimistic view on the company's future performance.
- Nokia Transformation: Bank of America upgrades Nokia from neutral to buy, highlighting its transition into an optical powerhouse, which positions the company favorably in the telecom equipment market and suggests significant growth potential ahead.
- Chime Financial Rating Initiated: Wells Fargo initiates coverage on Chime Financial with an overweight rating, recognizing its strong growth and profitability in the digital banking sector, and anticipates a positive impact from the upcoming tax season.
See More
